A.M. Pieczonka et al. / European Journal of Medicinal Chemistry 64 (2013) 389e395
393
4.1.1. Starting materials
120.8 (C(4), C(5)); 145.8, 129.5, 128.6, 127.7, 114.7, 112.6 (8 arom.
CH); 127.0 (C(2)); 48.8 (CH2); 9.9 (Me). HR-ESI-MS: 325.1295
([M þ H]þ, C17H17N4Oþ3 ; calc. 325.1295).
All solvents are commercially available and they were used as
received. Ethyl 3-oxido-1H-imidazole-4-carboxylate 3 was ob-
tained according to published procedure [22]. Carbohydrazides 4
were obtained from 3 by treatment with hydrazine hydrate
following previously published protocol [25].
4.1.2.5. 1-Benzyl-5-methyl-N0-[(Z)-(4-nitrophenyl)methylidene]-1H-
imidazole-4-carbohydrazide 3-oxide (6h). Yellowish crystals; yield:
97%; mp 264e265 ꢁC (MeOH). IR (nmax, cmꢂ1, KBr): 3081m, 1665vs
4.1.2. General procedure for synthesis of hydrazones 6
(C]O), 1614m, 1519s, 1342s. 1H NMR (600 MHz, DMSO-d6,
d, ppm):
To a stirred solution of a hydrazide 4 (1 mmol) in MeOH (5 mL)
at 20 ꢁC, an equimolar quantity of the carbonyl component 5 was
added slowly. The mixture was stirred for 16 h at room temperature
(6ae6g), or refluxed for 2 h (6he6k), the solution was concen-
trated, the resulting solid was treated with Et2O, filtered, and
crystallized from MeOH.
14.63 (1H, br. s, NH); 8.78 (1H, s, HC(2)); 8.52 (1H, s, HC]N); 8.30,
7.99 (4H, AA0BB0, JAB ¼ 9.0, AreH); 7.42e7.27 (5H, m, AreH); 5.27
(2H, s, CH2); 2.50 (3H, s, Me). 13C NMR (150 MHz, DMSO-d6,
d, ppm):
156.8 (C]O); 146.6 (C]N); 141.2, 135.7, 122.0 (3 arom. C); 132.5,
120.7 (C(4), C(5)); 129.5, 128.7, 128.5, 127.7, 124.5 (9 arom. CH);
127.1 (C(2)); 48.9 (CH2); 9.9 (Me). HR-ESI-MS: 380.1350 ([M þ H]þ,
1-Benzyl-5-methyl-N0-[(Z)-phenylmethylidene]-1H-imidazole-
4-carbohydrazide 3-oxide (6a), 1-Benzyl-N0-cyclohexylidene-5-
methyl-1H-imidazole-4-carbohydrazide 3-oxide (6b), 1-Benzyl-5-
methyl-N0-[(1Z)-1-phenylethylidene]-1H-imidazole-4-carbohydra
zide 3-Oxide (6c), were described in our earlier paper [25].
C
19H18N5Oþ4 ; calc. 380.1353).
4.1.2.6. 1-Benzyl-5-methyl-N0-[(Z)-(5-nitro-2-furyl)methylidene]-
1H-imidazole-4-carbohydrazide 3-oxide (6i). Yellowish crystals;
yield: 89%; mp 237e240 ꢁC (MeOH). IR (nmax, cmꢂ1, KBr): 3161m,
1680vs (C]O), 1607s, 1474s, 1362m, 1254m. 1H NMR (600 MHz,
4.1.2.1. 1-Benzyl-5-methyl-N0-[(Z)-(4-methoxyphenyl)methylidene]-
1H-imidazole-4-carbohydrazide 3-oxide (6d). Colorless crystals;
yield: 90%; mp 221e222 ꢁC (MeOH). IR (nmax, cmꢂ1, KBr): 3083m,
1663vs (C]O), 1607vs, 1510m, 1254m, 1170m. 1H NMR (600 MHz,
DMSO-d6, d, ppm): 14.71 (1H, br. s, NH); 8.76 (1H, s, HC(2)); 8.41
(1H, s, HC]N); 7.77, 7.17 (2H, 2d, J ¼ 4.2, furyl AreH); 7.42e7.27
(5H, m, AreH); 5.27 (2H, s, CH2); 2.49 (3H, s, Me). 13C NMR
(150 MHz, DMSO-d6, d, ppm): 156.8 (C]O); 152.2, 135.7, 127.7 (3
DMSO-d6,
d
, ppm): 14.24 (1H, br. s, NH); 8.72 (1H, s, HC(2)); 8.28
arom. C); 136.9 (C]N); 132.7, 120.6 (C(4), C(5)); 129.5, 128.7,
(1H, s, HC]N); 7.69, 7.01 (4H, AA0BB0, JAB ¼ 9.0, AreH); 7.42e7.26
(5H, m, AreH); 5.25 (2H, s, CH2); 3.80 (3H, s, OMe); 2.48 (3H, s, Me).
127.7, 116.3, 115.0 (7 arom. CH); 127.2 (C(2)); 48.9 (CH2); 10.0
(Me). HR-ESI-MS: 370.1145 ([M
370.1146).
þ
H]þ, C17H16N5Oþ5 ; calc.
13C NMR (150 MHz, ()DMSO-d6,
d, ppm): 161.4 (C]O); 156.3, 135.8,
127.4 (3 arom. C); 148.6 (C]N); 131.8, 120.9 (C(4), C(5)); 129.5,
129.3, 128.6, 127.7, 114.8 (9 arom. CH); 126.9 (C(2)); 55.8 (OMe);
48.8 (CH2); 9.9 (Me). HR-ESI-MS: 365.1608 ([M þ H]þ, C20H21N4O3þ;
calc. 365.1606).
4.1.2.7. 1,5-Dimethyl-N0-[(Z)-(5-nitro-2-furyl)methylidene]-1H-imid-
azole-4-carbohydrazide 3-oxide (6j). Yellowish crystals; yield: 84%;
mp 313e315 ꢁC (MeOH). IR (nmax, cmꢂ1, KBr): 3149m,1680vs (C]O),
1603m, 1477s, 1355s, 1269m. 1H NMR (600 MHz, DMSO-d6,
d, ppm):
4.1.2.2. 1-Benzyl-5-methyl-N0-[(Z)-(4-dimethyloaminophenyl)methyl-
idene]-1H-imidazole-4-carbohydrazide 3-oxide (6e). Colorless crys-
tals; yield: 89%; mp 252e254 ꢁC (MeOH). IR (nmax, cmꢂ1, KBr):
3088m, 2906m, 1664vs (C]O), 1603vs, 1524m, 1368m, 1181m. 1H
14.77 (1H, br. s, NH); 8.55 (1H, s, HC(2)); 8.39 (1H, s, HC]N); 7.77,
7.16 (2H, 2d, J ¼ 4.2, furyl AreH); 3.59 (3H, s, NMe); 2.54 (3H, s, Me).
13C NMR (150 MHz, DMSO-d6,
d, ppm): 158.8 (C]O); 152.2, 136.7 (2
arom. C); 136.9 (C]N); 132.5, 120.7 (C(4), C(5)); 116.2, 115.1 (2
arom. CH); 127.2 (C(2)); 32.5 (NMe); 9.7 (Me). HR-ESI-MS:
294.0830 ([M þ H]þ, C11H12N5Oþ5 ; calc. 294.0833).
NMR (600 MHz, DMSO-d6, d, ppm): 14.10 (1H, br. s, NH); 8.71 (1H, s,
HC(2)); 8.15 (1H, s, HC]N); 7.56, 6.74 (4H, AA0BB0, JAB ¼ 9.0, AreH);
7.42e7.26 (5H, m, AreH); 5.25 (2H, s, CH2); 2.97 (6H, s, Me2N); 2.48
(3H, s, Me). 13C NMR (150 MHz, ()DMSO-d6,
d, ppm): 160.0 (C]O);
4.1.2.8. 1-Cyclohexyl-5-methyl-N0-[(Z)-(5-nitro-2-furyl)methylidene]-
1H-imidazole-4-carbohydrazide 3-oxide (6k). Yellowish crystals;
yield: 74%; mp 222e225 ꢁC (MeOH). IR (nmax, cmꢂ1, KBr): 3105m,
2939m, 2856m, 1675vs (C]O), 1590s, 1472s, 1350m, 1266m. 1H NMR
152.1, 135.8, 122.0 (3 arom. C); 149.4 (C]N); 131.5, 121.1 (C(4), C(5));
129.5,129.1,128.6,127.7,112.2 (9 arom. CH); 126.9 (C(2)); 48.7 (CH2);
40.5 (Me2N); 9.9 (Me). HR-ESI-MS: 378.1923 ([M
þ
H]þ,
C21H24N5Oþ2 ; calc. 378.1924).
(600 MHz, DMSO-d6, d, ppm): 14.81 (1H, br. s, NH); 8.80 (1H, s,
HC(2)); 8.40 (1H, s, HC]N); 7.77, 7.16 (2H, 2d, J ¼ 4.2, furyl AreH);
4.1.2.3. 1-Benzyl-5-methyl-N0-[(Z)-(2-hydroxyphenyl)methylidene]-
1H-imidazole-4-carbohydrazide 3-oxide (6f). Colorless crystals;
yield: 89%; mp 229e232 ꢁC (MeOH). IR (nmax, cmꢂ1, KBr): 3140m,
4.14e4.09 (1H, m, CH); 2.61 (3H, s, Me); 1.96e1.80 (4H, m); 1.67e
1.39 (5H, m); 1.21e1.13 (5H, m). 13C NMR (150 MHz, DMSO-d6,
d,
ppm): 157.1 (C]O); 152.2, 133.7 (2 arom. C); 136.7 (C]N); 132.1,
119.9 (C(4), C(5)); 116.2, 115.0 (2 arom. CH); 124.9 (C(2)); 55.3 (CH);
32.9, 25.3, 24.9 (5 cyclohexyl CH2); 9.7 (Me). HR-ESI-MS: 362.1455
([M þ H]þ, C16H20N5Oþ5 ; calc. 362.1459).
1670vs (C]O),1616s,1590m,1277m.1H NMR (600 MHz, DMSO-d6,
d,
ppm): 14.55 (1H, br. s, NH); 8.76 (1H, s, HC(2)); 8.58 (1H, s, HC]N);
7.54e6.90 (9H, m, AreH); 5.27 (2H, s, CH2); 2.49 (3H, s, Me).13C NMR
(150 MHz, DMSO-d6, d, ppm): 157.9 (C]O); 156.3, 135.7, 120.5 (3
arom. C); 149.6 (C]N); 132.0, 119.1 (C(4), C(5)); 132.2, 130.3, 128.7,
119.8, 116.9 (9 arom. CH); 127.1 (C(2)); 48.8 (CH2); 9.9 (Me). HR-ESI-
MS: 351.1449 ([M þ H]þ, C19H19N4O3þ; calc. 351.1452).
4.2. Antibacterial assay
The in vitro antimicrobial activity of newly synthesized com-
pounds was evaluated against the reference strains of Gram-
negative (E. coli NCTC 8192, Proteus vulgaris ATCC 49990, Proteus
mirabilis ATCC 29906, Pseudomonas aeruginosa NCTC 6249), Gram-
positive (S. aureus ATCC 6538, S. aureus ATCC 29213, Enterococcus
faecalis ATCC 29212, S. epidermidis ATCC 12228) bacterial and fungal
(Candida albicans ATCC 10231) species. Moreover, the most active
(against the reference strains) compounds were examined against a
set of twelve clinical isolates of S. aureus from the collection
belonging to the Chair of Immunology and Infectious Biology,
4.1.2.4. 1-Benzyl-5-methyl-N0-[(Z)-2-furylmethylidene]-1H-imid-
azole-4-carbohydrazide 3-oxide (6g). Colorless crystals; yield:
78%; mp 220e221 ꢁC (MeOH). IR (nmax, cmꢂ1, KBr): 3138m, 1656vs
(C]O), 1627s, 1593s, 1276m. 1H NMR (600 MHz, DMSO-d6,
d, ppm):
14.30 (1H, br. s, NH); 8.73 (1H, s, HC(2)); 8.25 (1H, s, HC]N); 7.84,
6.89, 6.62 (3H, 3d, J ¼ 3.6, furyl AreH); 7.42e7.25 (5H, m, AreH);
5.25 (2H, s, CH2); 2.48 (3H, s, Me). 13C NMR (150 MHz, DMSO-d6,
d,
ppm): 156.5 (C]O); 149.9, 135.8, (2 arom. C); 138.6 (C]N); 132.0,